Skip to Main Content

Allergan (AGN) is appealing to the Supreme Court in an effort to stall generic competition to its best-selling dry-eye drug Restasis. But the pharma giant also faces a threat on a different front: a small Canadian drug maker advancing its own medicine that could prove superior to Restasis.

The experimental dry-eye medicine is called VOS, a shorthand moniker for voclosporin ophthalmic solution. It’s being developed by Aurinia Pharmaceuticals (AUPH), a drug maker based in Victoria, the capital of British Columbia located on the southern tip of Vancouver Island.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!